Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. (Q54326192)

27 May 2018

title

Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. (English)

1 reference

27 May 2018

peritoneal carcinomatosis

main subject

1 reference

7

Yasushi Yatabe

1 reference

27 May 2018

author name string

Takuya Saito

1

1 reference

27 May 2018

Hayao Nakanishi

2

1 reference

27 May 2018

Yoshinari Mochizuki

3

1 reference

27 May 2018

Seiji Ito

4

1 reference

27 May 2018

Yuichi Ito

5

1 reference

27 May 2018

Kazunari Misawa

6

1 reference

27 May 2018

Keigo Yamamichi

8

1 reference

27 May 2018

Eisaku Kondo

9

1 reference

27 May 2018

publication date

31 August 2014

1 reference

27 May 2018

published in

Gastric Cancer

1 reference

27 May 2018

volume

18

1 reference

27 May 2018

issue

4

1 reference

27 May 2018

page(s)

711-719

1 reference

27 May 2018

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Chemotherapy for metastatic gastric cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Delay to formalin fixation effect on breast biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-014-0417-4

HER2 expression and its clinicopathological features in resectable gastric cancer

21 January 2018

1 reference

12 December 2020

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1 reference

12 December 2020

Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays

1 reference

12 December 2020

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

1 reference

12 December 2020

Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection

1 reference

12 December 2020

Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines

1 reference

12 December 2020

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system

1 reference

12 December 2020

Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.

1 reference

12 December 2020

10.1007/S10120-014-0417-4

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018